ings could be due to a chance or unmeasured confounding and need confirmation in other studies, they do represent the first analytical data of this potential association. If true, the observed association could either be attributed to the unmasking of a latent demyelinating disease or to the emergence of a de novo demyelinating disease.

The rarity of demyelinating diseases limited the statistical power and capacity to adjust for or match on potential confounder variables. Thus, the estimates should be interpreted with caution because confounding cannot be excluded.

Nynne Nyboe Andersen, MD
BJörn Pasternak, MD, PhD
Mikael Andersson, MSc
Nete Munk Nielsen, MD, PhD
Tine Jess, MD, DMSc

Author Affiliations: Department of Epidemiology Research, Statens Serum Institut, 2300 Copenhagen S, Denmark.

Corresponding Author: Nynne Nyboe Andersen, MD, Department of Epidemiology Research, Statens Serum Institut, Artillerivej 5, DK-2300 Copenhagen S, Denmark (nyna@ssi.dk).


Author Contributions: Dr Nyboe Andersen had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: All authors.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Pasternak, Andersson, Nielsen, Jess.

Critical revision of the manuscript for important intellectual content: Pasternak, Andersen, Nielsen, Jess.

Statistical analysis: Nyboe Andersen, Andersen.

Obtained funding: Nyboe Andersen, Jess.

Study supervision: Pasternak, Nielsen, Jess.

Conflict of Interest Disclosures: Dr Nyboe Andersen has received funding for travel and speakers fee from MSD and speakers fee from Ferring. Dr Jess has received funding for travel and speakers fee from AbbVie. No other disclosures are reported.

Funding/Support: This study was supported by grants from the Lundbeck Foundation (grant No. R83-A7812), for Women in Science (by UNESCO and L’Oréal), the Beckett Foundation, and the Danish Colitis Crohn Association. Dr Pasternak is supported by the Danish Council for Independent Research (grant No. 4092-00155). Dr Jess holds a Female Research Leader grant (No. 09-066323) from the Danish Council for Independent Research.

Role of the Sponsor: The funding agencies had no role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; the preparation, review, or approval of the manuscript; or the decision to submit the manuscript for publication.


HEALTH CARE REFORM

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals

Most contemporary approvals of new cancer drugs are made on the basis of a surrogate end point, such as response rate or progression-free survival (PFS). When the approval is based on a surrogate end point, subsequent studies are advised and often obligated to clarify the drug’s effect on overall survival. One such drug is bevacizumab, which received accelerated approval on the basis of PFS for patients with metastatic breast cancer. Later findings revealed no improvement in overall survival and significant toxicity, which required a removal of marketing authorization.

A 2009 Government Accountability Office report criticized the US Food and Drug Administration (FDA) for failing to enforce postmarketing study commitments for surrogate approvals. Among the more than 400 postmarketing studies requested, approximately 30% were pending, ongoing, delayed, or terminated years later, yet the FDA never exercised its authority to remove a product from the market. For these reasons, we sought to investigate how often cancer drugs are approved based on a surrogate end point, whether subsequent studies for these drugs are reported, and whether the drugs improve overall survival.

Methods | We examined all marketing approvals by the FDA from January 1, 2008, through December 31, 2012. We identified the pathway for approval (accelerated vs traditional) and the surrogate end point used, such as tumor response rate or PFS. This investigation of published reports was exempt from institutional review board approval.

For all drugs approved on the basis of a surrogate end point, we performed a systematic search of the published literature using Google Scholar as of August 22, 2015, and identified any subsequent reports of the drug’s effect on overall survival. We credited a drug for improving overall survival if that drug improved survival as the sole investigational agent in any combination or in any line of treatment (eg, if approved for second-line treatment of metastatic disease, but the drug improved survival in first-line treatment, we would credit the drug as improving survival). We identified whether crossover (from the control arm to the investigational agent) was used in the randomized clinical trial or via a postprotocol expansion study. We analyzed the study data from August 22 to September 1, 2015.

Results | We identified 54 approvals made during our search period, with 36 drugs (67%) approved on the basis of a surrogate end point. Figure 1 shows all surrogate approvals, the efficacy end point at the time of approval, and the regula-
Figure 1. Oncology Drug Approvals Made on the Basis of a Surrogate End Point During the Study Period

14 Accelerated approvals

- Bevacizumab (2008): metastatic breast cancer
- Bevacizumab (2009): relapsed glioblastoma
- Brentuximab vedotin (2011): Hodgkin lymphoma or anaplastic large cell lymphoma
- Carfilzomib (2012): relapsed multiple myeloma
- Crizotinib (2011): ALK-positive NSCLC
- Dasatinib (2010): Ph-positive CML
- Everolimus (2012): subependymal giant cell astrocytoma with tuberous sclerosis
- Everolimus (2012): renal angiomylipoma with tuberous sclerosis
- Liposomal vincristine (2012): relapsed Ph-negative ALL
- Nilotinib (2010): Ph-positive CML
- Ofatumumab (2009): refractory CLL
- Omacetaxine (2012): chronic or accelerated-phase CML
- Ponatinib hydrochloride (2012): CML
- Pralatrexate (2009): relapsed peripheral T-cell lymphoma

5 Traditional approvals

- Bendamustine hydrochloride (2008): indolent NHL
- Bosutinib monohydrate (2012): CML
- Nab-paclitaxel (2012): locally advanced or metastatic NSCLC
- Romidepsin (2009): progressive CTCL
- Vismodegib (2012): locally advanced or metastatic BCC

Figure 2. Overall Survival Results for Cancer Drug Approvals Granted on the Basis of a Surrogate End Point

- Proven overall survival benefit
- No overall survival benefit
- Overall survival benefit unknown

Discussion | During our study period, 36 of 54 contemporary cancer drug approvals (67%) were made on the basis of a surrogate end point. With several years of follow-up, 31 (86%) of these approvals (57% of the 54 drugs approved) have unknown effects on overall survival or fail to show gains in survival. Our results show that most cancer drug approvals have not been shown to, or do not, improve clinically relevant end points.
Since 2008, the FDA has approved a higher percentage of drugs than previously, and cancer drugs are approved on the basis of surrogates that have poor correlations with overall survival. Our results suggest that the FDA may be approving many costly, toxic drugs that do not improve overall survival. Enforcement of postmarketing studies is therefore of critical importance.

Chul Kim, MD, MPH
Vinay Prasad, MD, MPH

Author Affiliations: Medical Oncology Service, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (Kim); Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, Portland (Prasad).

Corresponding Author: Vinay Prasad, MD, MPH, Division of Hematology and Medical Oncology, Knight Cancer Center, Oregon Health and Sciences University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239 (prasad@ohsu.edu).


Author Contributions: Drs Kim and Prasad had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Both authors.

Acquisition, analysis, or interpretation of data: Both authors.

Drafting of the manuscript: Prasad.

Critical revision of the manuscript for important intellectual content: Kim.

Statistical analysis: Kim.

Study supervision: Prasad.

Conflict of Interest Disclosures: None reported.


LESS IS MORE

Appropriate Prescribing for Patients With Diabetes at High Risk for Hypoglycemia: National Survey of Veterans Affairs Health Care Professionals

Evidence is accumulating that older individuals with diabetes mellitus have little to gain from the treatment burdens of stringent blood glucose control. In addition to concerns about increased mortality with tight control, some older patients with diabetes may also be at risk for hypoglycemia-related harms from medications prescribed to meet standard hemoglobin A1c (HbA1c) targets. This problem has motivated patient safety campaigns that cue health care professionals to limit medications for certain older patients (eg, those with an HbA1c level <7.5%, renal disease, or dementia) (to convert HbA1c to a proportion of total hemoglobin, multiply by 0.01). In this study, we examined beliefs of primary care health-care professionals (PCPs) to anticipate how PCPs might receive such recommendations.

Methods | We surveyed a national random sample of practicing nontrainee Department of Veterans Affairs (VA) PCPs, including physicians, nurse practitioners, and physician assistants. The study, including a waiver of signed informed consent, was approved by the institutional review board of the Ann Arbor VA Healthcare System and was conducted from October, 6, 2014, to December, 8, 2014. Participants answered questions about practice characteristics, performance incentives, beliefs about decreasing use of inappropriate services, and demographics. They also received a scenario about a 77-year-old man with long-standing type 2 diabetes mellitus at high risk for hypoglycemia (HbA1c level, 6.5%); severe kidney disease; and receiving glipizide, 10 mg, twice daily). Barriers to and facilitators of medication deintensification were identified using statements answered on a 4-point scale (strongly disagree to strongly agree) (Table 1). In addition, participants were asked to rate the level of difficulty they anticipated in following the Choosing Wisely recommendation (Table 1). Data were analyzed from March 18, 2014, to April 2, 2014. We used logistic regression to identify PCP and practice setting characteristics associated with anticipated difficulty following the Choosing Wisely HbA1c recommendation.

Results | Of 1222 eligible PCPs, 594 returned usable surveys (48.6% response rate; numbers vary due to item nonresponse). Of these, 311 (53.0%) were women, 138 (23.4%) were nurse practitioners, 46 (7.8%) were physician assistants, and 405 (68.8%) were physicians. A total of 217 PCPs (38.6%) thought that the 77-year-old patient at high risk for hypoglycemia would benefit if his HbA1c level was maintained below 7.0%, and 252 participants (44.9%) reported that they would not worry about potential harm from tight control. In addition, 236 PCPs (42.1%) would worry that deintensification in this context (HbA1c level, 6.5%) would lead to an HbA1c level that is outside of current performance measures; 132 of the participants (23.5%) worried that deintensification could leave them vulnerable to future malpractice claims. Table 1 presents participant responses to all scenario questions.

A total of 161 of 562 PCPs (28.7%) agreed it would be somewhat or very difficult to follow the Choosing Wisely HbA1c recommendation for older adults. The PCPs who agreed that maintaining the HbA1c level below 7.0% would benefit the patient and who reported worrying about malpractice claims were more likely to report difficulty following the HbA1c recommendation in the final adjusted regression model (P = .02). Conversely, PCPs who reported worrying that the patient would be harmed with tight blood glucose control were less likely to report difficulty following the HbA1c recommendation (P = .04) (Table 2).